# Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

> **NCT01594125** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Nintedanib high dose
- **DRUG:** Nintedanib low dose
- **DRUG:** Nintedanib medium dose
- **DRUG:** Nintedanib medium dose
- **DRUG:** Nintedanib high dose

## Key facts

- **NCT ID:** NCT01594125
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-11
- **Final completion:** 2015-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594125, "Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01594125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*